Arginase induction and activation during ischemia and reperfusion and functional consequences for the heart by Schlüter, Klaus-Dieter et al.
REVIEW
published: 11 March 2015
doi: 10.3389/fphys.2015.00065
Frontiers in Physiology | www.frontiersin.org 1 March 2015 | Volume 6 | Article 65
Edited by:
Gaetano Santulli,
Columbia University, USA
Reviewed by:
Amadou K. S. Camara,
Medical College of Wisconsin, USA
Sang-Bing Ong,
Universiti Teknologi Malaysia, Malaysia
*Correspondence:
Klaus-Dieter Schlüter,
Physiologisches Institut,
Aulweg 129,
35392 Gießen, Germany
klaus-dieter.schlueter@
physiologie.med.uni-giessen.de
Specialty section:
This article was submitted to Striated
Muscle Physiology, a section of the
journal Frontiers in Physiology
Received: 15 December 2014
Accepted: 07 February 2015
Published: 11 March 2015
Citation:
Schlüter K-D, Schulz R and
Schreckenberg R (2015) Arginase
induction and activation during
ischemia and reperfusion and
functional consequences for the heart.
Front. Physiol. 6:65.
doi: 10.3389/fphys.2015.00065
Arginase induction and activation
during ischemia and reperfusion and
functional consequences for the
heart
Klaus-Dieter Schlüter *, Rainer Schulz and Rolf Schreckenberg
Physiologisches Institut, Justus-Liebig-Univiersität Giessen, Giessen, Germany
Induction and activation of arginase is among the fastest responses of the heart to
ischemic events. Induction of arginase expression and enzyme activation under ischemic
conditions shifts arginine consumption from nitric oxide formation (NO) to the formation
of ornithine and urea. In the heart such a switch in substrate utilization reduces the impact
of the NO/cGMP-pathway on cardiac function that requires intact electromechanical
coupling but at the same time it induces ornithine-dependent pathways such as the
polyamine metabolism. Both effects significantly reduce the recovery of heart function
during reperfusion and thereby limits the success of reperfusion strategies. In this context,
changes in arginine consumption trigger cardiac remodeling in an unfavorable way and
increases the risk of arrhythmia, specifically in the initial post-ischemic period in which
arginase activity is dominating. However, during the entire ischemic period arginase
activation might be a meaningful adaptation that is specifically relevant for reperfusion
following prolonged ischemic periods. Therefore, a precise understanding about the
underlying mechanism that leads to arginase induction as well as of it’s mechanistic
impact on post-ischemic hearts is required for optimizing reperfusion strategies. In this
review we will summarize our current understanding of these processes and give an
outlook about possible treatment options for the future.
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Arginase Isoforms and Biological Activity
Arginase is an enzyme that catalyzes the hydrolysis of L-arginine into urea and ornithine. It
is expressed in two different isoforms. Arginase I is located in the cytosol and well-known
from hepatic metabolism in which arginase is responsible for the elimination of metabo-
lites from amino acid and nucleotide metabolism. The enzyme is expressed throughout the
body in endothelial cells and muscle cells (Gonon et al., 2012). In contrast to arginase I,
arginase II is predominantly located in the mitochondrial matrix and seems to be linked
directly to polyamine metabolism, although its exact function is not known (Morris, 2005).
The polyamine metabolism synthesizes polyamines such as spermine and spermidine that
are required for cellular growth. The rate limiting step of this pathway is the induction of
Abbreviations:NOS, nitric oxide synthase; TNF, tumor necrosis factor; ODC, ornithine decarboxylase; ROS, reactive oxygen
species; SOD, superoxide dismutase; Nor-NOHA, Nω-hydroxy-nor-L-arginine.
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ornithine decarboxylase (ODC) converting ornithine into
putrescine. Polyamines, such as putrescine, spermine, and sper-
midine, may act within cells but they can also be released from
cells. In the latter case they affect cell function as agonists of
calcium-sensing receptors (Smajilovic et al., 2010). Arginase II
may not be confined to the mitochondrial matrix when the
expression level is elevated. Moreover, arginase can also be found
in platelets where it plays a role in sickle cell disease not neces-
sarily requiring mitochondrial participation (Raghavachari et al.,
2007). When not specified within the text, the term arginase will
be used as a synonym for both isoforms.
Arginine as the main substrate of both isoforms of arginase is
also the substrate for the three isoforms of nitric oxide synthase
(NOS). Therefore, excessive activity of either NOS or arginase
reduces substrate availability for the other arginine consumer. In
fact, most cells express arginase and NOS isoforms at the same
time. In most cells enzymatic activity of each of these enzymes is
tightly regulated by direct protein modification or by induction
of enzyme expression. In case of arginase an increased activity of
arginase has consequences for both pathways: a loss of NO/cGMP
signaling and an improvement of polyamine metabolism. Exam-
ples for increased arginase activity and expression are found
in artherosclerosis, hypertension, inflammation, aging, stroke,
myocardial infarction, and heart failure to name just a few (Wu
and Meininger, 2000; Ryoo et al., 2008; Bagnost et al., 2010;
Heusch et al., 2010). It is commonly accepted that excessive acti-
vation of arginase is associated with disease progress. Whether
the final effect of arginase activation depends on the activa-
tion of arginase-dependent pathways (polyamine pathways) or
on the inhibitory effect on NO/cGMP-dependent pathways or
on both pathways remains elusive. Furthermore, at least in case
of atherosclerosis, arginase II may activate intracellular signal-
ing independent of its enzymatic activity (Xiong et al., 2013).
Regarding the role of arginase in endothelial dysfunction, argi-
nine metabolism seems to play a relevant role by either reduc-
ing arginine uptake (Martens et al., 2014), activation of arginase
II (Pandey et al., 2014), or activation of arginase I (Gao et al.,
2007). A precise understanding of the regulation and function
of arginase and a subsequent translation of these findings into
medical therapies will certainly improve clinical outcomes. The
current review will focus on the role of arginase during ischemia
and in particular during reperfusion.
Arginase Activation in Ischemic and
Post-Ischemic Hearts
Most, but not all investigators that studied the activity of arginase
in ischemic and post-ischemic cardiac tissues found a significant
increase in total arginase activity, arginase I expression, or both.
In principle, expression of arginase II can also be induced by
hypoxia as shown for human pulmonary artery smooth muscle
cells (Chen et al., 2014; Jin et al., 2014). However, whether induc-
tion of arginase II contributes to the increased arginase activ-
ity in the heart during ischemia and reperfusion remains to be
established. Most remarkable observations of increased arginase
activity were made at a very early time-point after the onset of
ischemia and reperfusion (Harpster et al., 2006; Grönros et al.,
2013). The underlying mechanism by which arginase I expres-
sion is induced has been evaluated in detail as described now.
Arginase I expression was identified as the strongest and fastest
transcriptional adaptation during ischemia and reperfusion in
the heart (Harpster et al., 2006). Several mechanisms seemed to
be responsible for this effect: At first, hypoxia and reoxygena-
tion damages cardiomyocytes because it leads to excessive cal-
cium load during ischemia and subsequent reoxygenation gener-
ates energy that allows a very strong contraction disrupting the
sarcolemmal membrane. This cell damage leads to a release of
intracellular material into the extracellular compartment (Hearse
et al., 1973). This hypercontraction-induced cell damage is the
basis for diagnosis of infarct size by quantification of plasma
levels of cardiac-specific enzymes, i.e., hs cTnI (= high sensi-
tive cardiac-specific troponin I). Such molecules that are released
by hypercontracture may have also a functional relevance in
the subsequent activation of arginase expression. Extracellular
RNA (eRNA), which is among intracellular materials released by
hypercontracture, triggers the activation of a membrane-bound
sheddase that, once activated, releases TNF-α (Cabrera-Fuentes
et al., 2014; see Figure 1). TNF-α has been identified as a pro-
inflammatory cytokine that activates arginase I (Schreckenberg
et al., 2015b). This observation is further based on experiments
with TNF-α−/−mice in which ischemia and reperfusion does not
lead to an induction of arginase I (Gao et al., 2007). TNF-α may
trigger this process via activation of the transcription factor AP-1
(Figure 1). A potential AP-1 binding site has been identified in
the promoter region of arginase and TNF-α activates the activ-
ity of the transcription factor AP-1 (Zhu et al., 2010). Hypoxia
directly recruits c-jun to AP-1 binding sites of the arginase-1
promoter (Singh et al., 2014). c-Jun binds together with activat-
ing transcription factor-2 at the AP-1 site, which initiates the
transactivation (Zhu et al., 2010). Acute myocardial infarction
is sufficient to induce the expression of 15 different genes that
are involved in assembly and activation of AP-1 within 15min
(Harpster et al., 2006). All these findings strongly support the
assumption that AP-1 activation plays a major role in adapta-
tion of arginine metabolism to hypoxia. Such a scenario would
also explain the more general finding that arginase activation
under ischemia and reperfusion is not specific for the heart but
represents a more general pathway by which tissues respond to
hypoxia because cell damage and loss of plasmalemmal integrity
is a characteristic feature of anoxic cell damage. As outlined in
the next section, hypoxic conditions trigger arginase I expression
in nearly all tissues. As mentioned above, arginase II can also be
induced by hypoxia. Themechanism has beenworked out on pul-
monary smooth muscle cells. Hypoxia induced the expression of
miR-17-5p that then triggers the up-regulation of arginase II (Jin
et al., 2014). Activation of PI3-kinase-Akt signaling pathways can
attenuate this activation (Chen et al., 2014). However, it remains
to be clarified whether similar concerns hold for arginase II in the
heart during acute ischemia and reperfusion.
At least within cardiac tissue, induction of arginase I expres-
sion is a strong and early response of cells to hypoxic stress. This
leads to the question whether this is exerts a protective effect? At
first, during the hypoxic period the arginine-consuming counter-
part of arginase, NOS, is functionally inactive, because formation
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FIGURE 1 | Effect of hypoxia (ischemia) on arginine metabolism.
Direct effects of low pO2 are the translocation of c-jun in AP-1 dimers,
thereby activating AP-1 transcriptional activity, an activation of PKCα and
subsequent activation of arginine transporters (CAT2) and inhibition of
constitutively expressed NOS isoforms (eNOS and nNOS). Indirect
effects of low pO2 are loss of sarcolemmal integrity in some cells (see
left), leading to the release of intracellular particles, such as RNA
(eRNA), that activates a sheddase (TACE) thereby releasing TNFα. TNFα
augments the hypoxia-induced cell damage by activation of AP-1 and
increasing arginase (Arg) expression, by activation of arginase activity via
nitrosylation and reducing the KM value for the enzymatic reaction, and
ROS-dependent inhibition of NOS activity.
of NO from arginine requires molecular O2. In the absence of O2,
NOS works in an uncoupled mode generating reactive oxygen
species (ROS) that damages cells and this may be relevant at the
onset of reperfusion. In this context it is also likely to understand
that ROS stimulates arginase expression as well (Figure 1). More-
over, TNF-α activates ROS formation. In other words, ROS for-
mation initiates a negative feedback loop by which arginine, the
substrate of NOS, is removed in a condition in which uncoupled
NOS forms damaging ROS.
Activation of arginase cannot reduce the level of overburden
ROS formation alone. In transgenic mice with over-expression
of TNF-α, it was found that the subsequent development of
endothelial dysfunction can be reduced by administration of
tempol, a superoxide dismutase (SOD) mimetic and radical
scavenger (Zhang et al., 2010). In chronic ischemic injury, up-
regulation of arginase I and SOD-2 are commonly found and
it remains speculative whether the up-regulation of SOD-2 is
not sufficient for ROS scavenging or whether arginase I activa-
tion and SOD-2 activation play divergent roles (Roy et al., 2009).
Another piece of this puzzle is the finding that increased ROS
formation favors S-nitrosylation of arginase thereby decreasing
the Km for L-arginine again favoring the reduction of arginine
levels. Furthermore, activation of protein kinase C (PKC)-α in
endothelial cells further decreases the activity of NOS by activa-
tion of the transcription factor AP-1 that induces not only the
expression of arginase but also that of the up-take of arginine by
induction of the expression of CAT-2 transporters (Figure 1). At
the same time, PKC-α promotes eNOS phosphorylation at Thr
495 resulting in decreased NO production (Visigalli et al., 2010).
Finally, in the ischemic/reperfused heart, arginase I induction is
opposed by eNOS down-regulation (Hein et al., 2003). All these
molecular responses to hypoxia shift arginine consumption from
the NO pathway toward the arginase-dependent pathways and
this may be a strategy of cells to withstand hypoxic stress. In
conclusion, under conditions in which NOS cannot synthesize
NO, reducing the intracellular arginine pool by arginase activa-
tion may protect cells. However, high concentrations of arginine
can reduce the expression of NOS which is then lacking in the
reperfused tissue. All these examples suggest that reducing argi-
nine levels will protect hypoxic cells from irreversible damage
(Figure 2-I).
This advantage of high arginase activity during ischemia may
switch into a strong disadvantage as soon as the tissue is reper-
fused. Now, high arginase activity contributes to the reduced
NOS activity in post-ischemic tissues resulting in low perfusion
and prolongation of ischemic time. Moreover, low NO/cGMP
levels contribute to reperfusion injury, loss of endothelial bar-
rier function, and increase the susceptibility to cardiac arrhyth-
mia (see Section Post-Ischemic Consequences of Reduced NO
Formation and Contribution of Arginase for details). At the
same time, the release of polyamines acts via activating of
calcium-sensing receptors and this affects the rather sensi-
tive intracellular calcium handling in cells during reperfusion
(Figure 2-II).
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FIGURE 2 | Relative contribution of cellular protection vs. cellular
damage of the two main arginine pathways. Panel (I): During ischemia
the activation of arginase (Arg) activity reduces the effect of physiological
levels of NO on cellular metabolism thereby and reduces otherwise
accumulating arginine levels. At this time, inhibition of arginase would be
detrimental for the outcome. Panel (II): During early reperfusion, dominance
of arginine pathway limits the protective role of NO, specifically on
SR-calcium load that triggers fatal arrhythmic events. Moreover, the activated
arginase/polyamine pathway potentially augments calcium overload by
release polyamines that act on calcium receptors (CaR). Now, the further
outcome will benefit from arginase inhibition. Panel (III): At late reperfusion,
inflammatory pathways have induced the expression of iNOS that generates
detrimental amount of NO that are potentially damaging. In this phase, an
inhibition of arginase will be again detrimental, because then more arginine
can be converted into NO. Green arrows indicate activation and red arrows
indicate inhibition.
Arginase Activation in Non-Cardiac
Tissues
As mentioned above, arginase activation during hypoxia is not
tissue specific. Like the heart, arginase activation occurs in the
liver and some other tissues such as the detrusor (Kawano et al.,
2006). Although this review is focussed on the heart, it seems
to be important to compare the effect of ischemia on arginase
activity in the heart with that in other organs to better under-
stand the relevance of arginase activity in cells. Investigating
the effect of ischemia on arginase activity was first performed
in the liver. In the liver arginase is the most important enzyme
that protects the organism from ammonia intoxication. Exces-
sive release of arginase from liver transplants is a severe clinical
problem that occurs in the reperfusion period. Arginase is able
to metabolite plasma arginine and thereby reduce the substrate
availability for NOS and arginase. Subsequently, a drop in plasma
arginine and nitrite, a stable end product of NO, and an increase
in plasma ornithine can be observed. Functionally, this leads
to hemodynamic alterations specifically in the lung and liver
(Roth et al., 1994; Längle et al., 1995; Silva et al., 2005). Supple-
mentation of arginine could reduce liver transplant preservation
injury in rats with orthotopic liver transplantation (Yagnik et al.,
2002). Vice versa, inhibition of arginase by a specific inhibitor
of arginase, Nor-NOHA, stabilized liver histology and function
(Reid et al., 2007; Jeyabalan et al., 2008). A stabilization of
arginase activity could be achieved by ischemic pre-conditioning
of the liver (Ofluoglu et al., 2006). Moreover, administration of
adrenomedullin, a multifunctional peptide with a putative ben-
eficial role after ischemic insults, normalized arginase activity
and NO formation. Interestingly, it reduced also the induction
of the pro-inflammatory TNF-α pathway (Kerem et al., 2008).
As outlined already, TNF-α is a likely candidate for arginase
induction. Collectively, the data show a strong induction of
arginase activity in ischemic/reperfused liver tissue that leads to
a substrate deficit for NOS and thereby contributes to the post-
ischemic tissue damage. Therefore, the situation in the liver is
similar to that of the heart and supports translation of these
findings to heart protection against ischemia and reperfusion
injury.
On the other hand, reducing arginine pools by hyperacti-
vation of arginase will also have beneficial effects as it limits
the activity of iNOS in macrophages (Figure 2-III). Indeed pro-
inflammatory macrophages (M1 cells) express large amounts of
iNOS while anti-inflammatory macrophages that are involved
in wound healing (M2 cells) express large amounts of arginase.
Unfortunately, M2 macrophages are not only responsible for
wound healing as for example in post-ischemic tissues but
also for tumor growth. The relationship between M1 and M2
macrophages can be triggered by a specific tyrosine kinase,
namely the Ron receptor tyrosine kinase, that upregulates Fos
and enhances binding of Fos to the AP-1 binding site that
has already been identified as a promoter element required for
arginase I induction (Sharda et al., 2011). M2 macrophages play a
distinctive role in reperfusion injury of the kidney. In the kid-
ney M2 macrophages trigger the repair process days after the
ischemic insult (Lee et al., 2011). Indeed, the role of arginase acti-
vation in post-ischemic tissue differs between the kidney on the
one hand and the liver and heart on the other hand. Whereas,
arginase is activated in liver and heart, arginase activity is reduced
in post-ischemic kidneys. In the kidney increased NO produc-
tion leads to augmented tubular injury. Hypoxia leads to an up-
regulation of CAT-2 thereby providing arginine as a substrate for
eNOS and iNOS (Schwartz et al., 2002). In addition, arginase I
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and arginase II expression is reduced in post-ischemic kidney in
contrast to the liver and heart. Erbas et al. showed that admin-
istration of N-acetylcysteine normalizes arginase activity in the
kidney and improved the situation following ischemia and reper-
fusion (Erbas et al., 2004). Noteworthy, carefully measurements
of renal arginase activity 2 weeks after the insult have revealed an
up-regulation of the enzyme in the kidney that is required for the
proliferative repair of the damaged kidney (Bogatzki, 1963). As
in the kidney, ROS in the presence of high NOS activity trigger
neurological disorders to hypoxia/anoxia in brain and improving
arginase activity is again associated with protection (Swamy et al.,
2010).
Collectively these data show different roles for arginase in
hypoxic/reoxygenated tissues and indicate that a simple relation-
ship between tissue damage and arginase activity is unlikely to be
identified. Concerning the consequences of arginase activation in
the heart, wemay conclude from these studies on non-cardiac tis-
sues that arginase activity affects different physiological activities
in post-ischemic tissues that are linked to wound healing, tissue
repair, and cell function. The data suggest that arginase activation
may be necessary for some post-ischemic physiological adapta-
tion but may also be detrimental for other ones. Like the kidney
pharmacological options to affect the arginase activity will need
to define the best time-window to either improve or inhibit acti-
vation. The consequences for arginase activity in the heart will be
mentioned in the next section.
Post-Ischemic Consequences of Reduced
NO Formation and Contribution of
Arginase
As outlined above, arginase activation increases the formation
of ornithine but also limits the substrate availability for NOS.
Substrate limitation causes reduced NOS activity and NO has
repeatedly shown before to be important for proper heart func-
tion (Rassaf et al., 2006). Reduced NOS activity may reduce ROS
formation during ischemia but low NO levels are a common
problem in post-ischemic hearts. NOS activity in endothelial cells
is required for proper perfusion of the heart and as well as for
the anti-thrombotic activity of NO. Impaired endothelial func-
tion in post-ischemic hearts could be restored by inhibition of
arginase activity as repeatedly been shown (Hein et al., 2003; Gao
et al., 2007; Grönros et al., 2013). Furthermore, NOS activity is
also important within cardiomyocytes where NO/cGMP signal-
ing contributes to calcium oscillation during the phase of reper-
fusion, although this may also be responsible for cell damage
and arrhythmia. Indeed cardiac de-synchronization is a major
problem in the early phase of reperfusion. NO/cGMP is required
for normal cardiac function as it regulates calcium handling,
ion channel open probability and thereby action potential dura-
tion and other aspects of cardiac function. Among them are
effects on cellular cAMP levels by cGMP-dependent inhibition of
phosphodiesterase (PDE) II, protein kinase G-dependent down-
regulation of voltage-dependent L-type Ca2+ currents, desensiti-
zation of cardiac myofilaments by phosphorylation of troponin
I, and metabolic effects. These consequences of reduced NO in
cardiomyocytes are reviewed by Massion et al. (2005). Despite
clear effects of cGMP on calcium currents, NO/cGMP also mod-
ulate ATP-sensitive K+ channels, the hyperpolarization-activated
pacemaker current If, and voltage-dependent fast Na
+ currents
(Fischmeister et al., 2005). Furthermore, while NO/cGMP path-
ways inhibit cardiac hypertrophy, an activation of arginase-
dependent polyamine metabolism is pro-hypertrophic (Schlüter
et al., 2000; Booz, 2005). As expected some of these stres-
sors could be minimized by improving NO/cGMP signaling in
post-ischemic hearts. Moreover, uncoupling of NOS caused by
hypoxia increases ROS formation and excessive ROS, due to
oxidative stress, directly impairs cardiac function by formation
of disulfides cross-bridges at tropomyosin (Canton et al., 2006).
As a consequence arginase activation in post-ischemic hearts may
have detrimental effects due to the substrate limitation of NOS
and may contribute to NOS inefficiency at that time points.
Although increased substrate availability of arginine during
reperfusion may allow NOS to generate NO/cGMP, the interac-
tion between arginase and NOS is more complex than perceived.
Indeed, a clinical trial that was aimed to increase substrate avail-
ability by administration of arginine to post-infarct patients had
to be stopped due to lack of benefit and, even more important,
risk of increased mortality (Schulman et al., 2006). These data
indicate a detrimental effect of arginase-dependent pathways in
the post-ischemic period. As the polyamine metabolism is one of
the major pathways activated by arginase activity we will discuss
the consequences of polyamine metabolism for the post-ischemic
heart next.
Post-Ischemic Consequences of Increased
Polyamine Metabolism and Contribution of
Arginase
Arginase activation not only limits the activity of NOS isoforms
but also generates the substrate for the polyamine metabolism of
ornithine. An activation of the polyaminemetabolism is normally
associated with anabolism. In terms of cardiac tissue, activation
of polyamine metabolism is required for cardiac hypertrophy. An
activation of the polyamine metabolism critically depends on the
induction of ODC, the rate limiting enzyme of the polyamine
metabolism. Therefore, activation of arginase and ODC creates
a situation in which synthesis of polyamines is most likely. The
polyamine metabolism in general must be considered as a mean-
ingful adaptive mechanism because it allows cardiac hypertro-
phy that means that survived cardiomyocytes can increase the
number of their contractile units, the sarcomers. Furthermore,
release of polyamines can initiate an autocrine loop that acti-
vates calcium-sensing receptors on cardiomyocytes that by itself
increase cardiac power (Schreckenberg et al., 2015a). However,
as often in physiology it is difficult to adapt the right power of
activation. If the activation of the polyamine metabolism is exces-
sive the same pathway favors the induction of apoptosis (Gior-
dano et al., 2010; Mörlein et al., 2010). Moreover, as activation
of calcium-sensing receptors activates a Gαq-dependent signal-
ing in cardiomyocytes this involves the activation of IP3 recep-
tors that trigger again arrhythmic events (Schreckenberg et al.,
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2015a). Collectively, activation of arginase in the post-ischemic
myocardium has an increased risk of mal-adaption.
Experiences with Arginase Inhibition in
Ischemic and Reperfused Hearts
As outlined above, a successful use of arginase inhibitors to
improve post-ischemic recovery is limited at present by lack
of knowledge about exact time, duration, and amount of inhi-
bition. Nevertheless, recent studies have mostly shown bene-
ficial effects if arginase inhibition was performed during the
early phase of reperfusion. The majority of these studies have
revealed that arginase inhibition significantly improves NO pro-
duction in post-ischemic hearts (Jung et al., 2010; Gonon et al.,
2012; Tratsiakovich et al., 2013). Moreover, inhibition of arginase
before reperfusion reduced infarct sizes via preserved NO pro-
duction (Grönros et al., 2013). Another potential mechanism by
which inhibition of arginase during or immediately after reper-
fusion reduces reperfusion injury lies in the activation of PKC-
ε and opening of mitochondrial ATP-dependent K+ channels
(mitoKATP). However, it remains unclear whether this already
clarifies the role of arginase during reperfusion injury of the
heart. Pharmacological activation of PKC-ε failed to improve
strong end-points such as death and heart failure albeit reduction
in infarct size (Mochly-Rosen et al., 2012). Furthermore, dietary
supplementation of arginine in post-infarct patients to attenu-
ate arginase-induced arginine depletion in target cells turned out
to be not effective (Schulman et al., 2006). Even more disap-
pointing, this trial had been stopped for increased mortality in
the treatment group. Promising experimental data show a reduc-
tion in reperfusion injury by inhibition of arginase. However,
up-regulation of arginase-2 in erythropoietin-treated rat hearts
showed improvements in contractility and reduced myocardial
(Lu et al., 2012). In a recent study on isolated rat hearts, Yang
and colleagues provided evidence that inhibition of arginase I
activity in red blood cells increases NO release from erythrocytes
thereby improving post-ischemic recovery (Yang et al., 2013).
While it is easily to understand that increased NO may improve
post-ischemic recovery, it is difficult to explain why the inhi-
bition of tissue-specific arginase activation does not play a role
in these hearts unlike the inhibition of arginase in erythrocytes.
Finally, in the setting of chronic ischemia, arginase activity is
not related to coronary microvascular dysfunction (Sodha et al.,
2008). Collectively, it remains unclear whether the hypothesis of
substrate limitation is really cause of arginase-dependent mal-
function in post-ischemic hearts and how post-ischemic hearts
benefit mostly from arginase inhibition.
Possible Targets to Modify Arginase
Activity and the Consequences of Arginase
Activation in Post-Ischemic Hearts
Most studies published to date have used the arginase-specific
inhibitor Nω-hydroxy-nor-L-arginine (Nor-NOHA) to inhibit
arginase during reperfusion. Nor-NOHA has the advantage
not to interfere with NOS. Most but not all data published
to date are promising (see above) but it remains unclear
whether treatment with an arginase subtype unspecific inhibitor
is optimal. Consequently, the development of other arginase
inhibitors underway. Congeners of (R)-2-Amino-6-borono-2-
(2-(piperidin-1-yl)ethyl)hexanoic acid have been shown to bind
preferentially to arginase I, have antagonistic effects and are orally
bioavailable (Van Zandt et al., 2013). Such compounds may be
used to identify isoform specific effects of arginase in the future.
Another problem might be the timing of inhibition. Arginase
activation may be required during ischemic insults, detrimental
during the early phase of reperfusion but again required at later
time points to shift macrophage activity from pro-inflammatory
M1 to anti-inflammatory M2 subpopulation. Long-time follow-
ups are required to define electrophysiological remodeling and
such data are not yet reported. As indicated in case of PKC-ε,
reduction of infarct size alone is not sufficient. Another point that
has to be clarified in the future is whether arginase inhibition is
optimal or whether upstream elements of arginase induction are
more effective. Alternatively to arginase inhibition an inhibition
of TNF-α activation that attenuates arginase I activation might
be more effective. TNF-α knock-out mice had no up-regulation
of arginase. Subsequently, inhibition of a sheddase that releases
bound TNF-α during hypoxia was sufficient to attenuate arginase
induction (Schreckenberg et al., 2015b). Unlike the direct inhi-
bition of arginase, such an approach does not block arginase
activity in M2 macrophages. Therefore, a better understanding
of the mechanism by which arginase is activated and contributes
to reperfusion injury will lead to more specific targets to interfere
with these pathways. If substrate competition between NOS and
arginase is the main problem at the time of reperfusion, citrulline
rather than arginine supplementation may be of specific advan-
tage. Citrulline has less side effects, can be better administrated
orally than arginine, because it is not metabolized in the liver, and
can be converted into arginine at the site of action within the cell
due to the close physical association between argininosuccinate
lyase and eNOS (Romero et al., 2006; Smith et al., 2006).
Conclusive Remarks
Arginase activation is a common event in hypoxic tissues includ-
ing the heart. Recent development of reperfusion therapies has
led to a situation in which high arginase activity at the onset of
reperfusion participates in reperfusion-induced damage. There-
fore, there seems to be a therapeutic window by which either
attenuation of arginase induction of inhibition of arginase activ-
ity attenuates reperfusion damage. The optimal timing of phar-
macological interference has still to be defined as well as the
optimal time point. Figure 2 summarizes these assumptions.
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